The mitochondrion is both author and subject. What is established, and the far larger space of what is not.
Almost every peptide discussed on this site is built from instructions in the cell nucleus. MOTS-c is not. It is encoded in mitochondrial DNA — the small, separate genome that mitochondria carry from their own evolutionary past.
That makes it genuinely unusual. It is a 16-amino-acid peptide, and the mitochondrion is both its author and its subject.
Its evidence profile is worth stating up front. There is a large animal literature. There is essentially one human trial, and that was of a different molecule.
Your body makes MOTS-c during exercise and fasting. It behaves like a hormone: released from mitochondria, circulating in blood, carrying a message about how cells should handle energy.
The message arrives at AMPK, the enzyme that acts as a cell's fuel gauge. When energy runs low, AMPK switches on and shifts the cell toward producing energy rather than storing it.
The route MOTS-c takes to get there is indirect and rather elegant. It interferes with the folate cycle, which is linked to purine synthesis. That interference causes a metabolite called AICAR to accumulate, and AICAR activates AMPK directly.
Once AMPK is active, three things follow:
That combination is close to what training produces. So MOTS-c is often called an exercise mimetic: something that copies part of what exercise does at cell level.
Under metabolic stress, such as glucose restriction, MOTS-c moves out of the cytoplasm and into the nucleus. It can do so in as little as 30 minutes, and the move depends on AMPK.
Once there, it acts on gene expression, interacting with NRF2, the transcription factor governing antioxidant response genes.
Take a moment with that. A peptide written in the mitochondrial genome travels to the nucleus and shapes which nuclear genes switch on. It was the first mitochondrial-encoded peptide shown to do this. So MOTS-c is not only a metabolic signal. It also helps run the cell's stress defences.
A 2026 study in Free Radical Biology and Medicine sharpened the picture considerably.
Researchers gave MOTS-c to mice and measured mitochondrial function in skeletal muscle directly. Energy production improved — but the amount of respiratory protein did not increase.
The mitochondria already present were working better. Nothing new had been built.
The same work found fewer reactive oxygen species and less oxidative protein damage. The mechanism ran through PGC-1α and AMPK, confirmed in knockout mice. So alongside "build more mitochondria," MOTS-c also carries "run the existing ones better, and protect them."
MOTS-c is exercise-induced, and the numbers are striking. Skeletal muscle expression rises roughly twelve-fold after exercise. Circulating levels rise around 50%, then return to baseline within about four hours.
Levels also fall with age. In middle-aged men, circulating MOTS-c runs about 11% below young men. In older men it is about 21% below. That decline tracks the metabolic changes of ageing.
This is the finding to keep hold of, and it is the most useful thing in the literature.
In 2020, researchers put the question directly: could MOTS-c rescue cells carrying a severe mitochondrial DNA mutation? It could not. Neither added MOTS-c nor the cells' own supply improved function there.
The implication is precise: MOTS-c requires working mitochondria to act on. It is an optimisation signal, and a signal needs functioning machinery to receive it. Where the machinery is badly damaged, there is nothing for the message to do.
That single result explains more about variable responses than any amount of anecdote.
Here the honest account is short.
The only meaningful human data comes from CB4211, a stabilised synthetic analogue developed by CohBar. It is not MOTS-c itself. A phase 1a/1b trial finished in 2021. First 65 healthy adults for safety, then 20 adults with obesity and fatty liver, given 25 mg daily for four weeks.
That group showed ALT down 21%, against a 4% rise on placebo. AST fell 28% and fasting glucose 6%. Just over a third achieved more than a 30% relative cut in liver fat. Tolerability was good, with mild injection-site reactions the main adverse event.
Encouraging — and it is one small trial, of a modified molecule, over four weeks.
Everything else comes from animals and cultured cells. That includes insulin sensitivity, prevention of diet-induced obesity, running capacity in old mice, bone metabolism, cardiac protection, muscle preservation and liver protection. The preclinical picture is broad and consistently favourable. It is also not human evidence. The gap between the two is where most peptide claims go wrong.
Not approved by the FDA for human use.
Since 2024 it has sat on the WADA Prohibited List, under S4.4 for metabolic modulators, as an AMPK activator. It remains prohibited. Anyone subject to anti-doping testing should treat that as decisive.
Three, and none is close to settled.
Dose. Animal work used milligram-per-kilogram doses. Species scaling is not a simple weight conversion, and no dose-finding study exists in humans for the native peptide.
Duration. Nothing published follows humans on MOTS-c over months. The four-week analogue trial is the longest human exposure on record.
Whether the animal findings transfer at all. Mice are not small humans, and mitochondrial biology carries species differences that matter. The 2020 negative result shows the effect is conditional even in cells.
What is established is that MOTS-c is real, endogenous, exercise-responsive, declines with age, and acts through AMPK and the nucleus. What happens when it is given to a person over time is, at present, unknown.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
